Wednesday, June 10, 2026

pharma · Crohn's Disease · Ulcerative Colitis (UC)

AbbVie

AbbVie is a pharma organization headquartered in Hamilton, CN. Primary therapeutic focus areas include Crohn's Disease, Ulcerative Colitis (UC), Psoriatic Arthritis, Rheumatoid Arthritis, Hidradenitis Suppurativa. NovaPh

1 Waukegan Road, North Chicago, Illinois 60064, US HQ
60,084 Employees
NMPA registrant Type
Company details
Status
Public
HQ
1 Waukegan Road, North Chicago, Illinois 60064, US
Employees
60,084
Programs
41
Drugs
32
Patents
25
Clinical program

ABT-493

Phase 1 · small molecule · Hepatic Impairment

ABT-493 for Hepatic Impairment is a Phase 1 program (small_molecule) at AbbVie with 1 ClinicalTrials.gov record(s).

← All AbbVie projects Phase 1 small molecule completed

Internal code M13-604

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
AbbVie
Phase
Phase 1
Modality
small_molecule
Indication
Hepatic Impairment
Status
completed
Trials
1

Clinical trials